AFFYMAX (NASDAQ:AFFY)
20.23
0.03 (0.15%)
| AFFYMAX (NASDAQ:AFFY) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $20.26 | 52 Week High | $25.64 | ||
| Open | $20.23 | 52 Week Low | $11.79 | ||
| Day High | $20.23 | P/E | N/A | ||
| Day Low | $20.23 | EPS | $-5.14 | ||
| Volume | 748 | ||||
| More AFFY Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| HGSI | 2 | MDVN | 2 |
| MNKD | 2 | MNTA | 2 |
| ACOR | 2 | REGN | 2 |
| ALTH | 2 | VRTX | 2 |
| AMGN | 2 | AMLN | 2 |
| DNDN | 2 | ELN | 2 |
Entities who have mentioned AFFY
- Robert W Baird | View Related Stories »
- RBC Capital | View Related Stories »
- Lazard | View Related Stories »
- Cowen & Co | View Related Stories »
- JPMorgan | View Related Stories »
- HealthCor | View Related Stories »
- Needham & Company | View Related Stories »
- Soleil Securities | View Related Stories »
- Argus | View Related Stories »
- Thomas Weisel Partners Group | View Related Stories »
- SAC Capital | View Related Stories »
- Steven A. Cohen | View Related Stories »
- Piper Jaffray | View Related Stories »
- UBS | View Related Stories »
- Goldman Sachs | View Related Stories »
- Merrill Lynch | View Related Stories »
- Notable Analyst Rating Changes | View Related Stories »
- Morgan Stanley | View Related Stories »
- After-Hours Movers | View Related Stories »
- Stock Buyback | View Related Stories »
- S3 | View Related Stories »
StreetInsider.com Major News for AFFY
View All ReportsStreetInsider.com Reports on AFFY
- Affymax (AFFY) Completes Hematide Phase 3
- BioCentury Publishes BioTech Picks for FY10 (HGSI, VRTX, AMGN, More...)
- Baird Reiterates an 'Outperform' on Affymax (AFFY); Remain Buyers Ahead of Hematide Phase III Readouts
- Affymax (AFFY) Closes Stock Offering, Receiving Net Proceeds of $80M
- Affymax (AFFY) Prices 4.1M Shares at $18.25/Share
View All Press ReleasesCompany Press Releases on AFFY
- Affymax to Present at the 12th Annual BIO CEO & Investor Conference
- Affymax Completes Treatment and Last Patient Follow-up in Phase 3 Program for Investigational Drug, Hematide(TM), to Treat Anemia in Chronic Renal Failure
- BioCentury Publishes Investor Picks for New Biotech Bellwethers in 2010
- Affymax to Present at the 28th Annual JP Morgan Healthcare Conference
StreetInsider Reports on AFFY by Category
View All BlogsBlogs on AFFY
- FDA Calendar Updates: ABT, AFFY, AZN, LLY, MELA, PFE, SOMX, VPHM
- Analyst calls: MER, BAC, EXC, ABV, PPL, BBT . . .
- Analyst calls: MER, BAC, EXC, ABV, PPL, BBT . . .
- Analyst initiations: Telefonica, Affymax, Hatteras Financial
- Cancer Stocks: Lagging Again
View All FilingsSEC Filings on AFFY
- Form 4 AFFYMAX INC For: Jan 07 Filed by: Cleveland Paul B
- Form 4 AFFYMAX INC For: Jan 07 Filed by: Love Steven
- Form 4 AFFYMAX INC For: Jan 07 Filed by: Venteicher Robert
- Form 4 AFFYMAX INC For: Jan 07 Filed by: Duliege Anne-Marie
- Form 4 AFFYMAX INC For: Jan 07 Filed by: Morris Arlene
Comments on AFFY
No comments are currently available.
